AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

When it comes to dividend investing, there are two basic paths you can take. If you can't decide which dividend investing ...

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...

The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue.

The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue. The ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie and W.P. Carey offer dividend-seeking investors a combination of growth and high yields. AbbVie's more than quadrupled its payout since 2013 and the pharma stock still offers a high yield.